Skip to content
DataLookout
Menu

NCT07918898

Comparison of Pharmacokinetic/Pharmacodynamic Characteristics and Safety of GZR101-80 Injection With Separately Injected, Simultaneous Doses of GZR33 Injection and Insulin Aspart

StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below.

  1. Notable Recruitment opened
    • Start date changed from estimate of Oct 29, 2026 to Nov 2, 2026
    • Study sites: 0 to 1
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

AUCIAsp,0-6h
Timeframe: 0-6 hours after dosing
AUC GZR33, 0-24h
Timeframe: 0-24 hours after dosing

Secondary (3)

AUCGZR33, 0-∞
AUC IAsp, 0-∞
Incidence of adverse events

Arms and interventions

GZR101 80 InjectionExperimental
GZR33 Injection + Insulin Aspart InjectionExperimental

Drugs: GZR101 80 Injection, GZR33 Injection, Insulin Aspart Injection

Sites

1 site in 1 country

  • Medical Ethics Committee of Bishan Hospital of ChongqingChongqing, China